Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Allometric scaling may be used in drug development to predict the pharmacokinetics of xenobiotics in humans from animal data. Although allometry may be successful for compounds that are excreted unchanged or that are oxidatively metabolized (with corrections for metabolic capacity), it has been more challenging for compounds excreted primarily as conjugates in bile. (S)-10, 11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[ a, d]cycloheptene-10-acetic acid (SB-265123) is a novel alphavbeta3 ("vitronectin receptor") antagonist. In this study, the in vivo pharmacokinetics and in vitro plasma protein binding of SB-265123 were examined in four species: mice, rats, dogs, and monkeys. In monkeys and dogs, SB-265123 exhibited moderate clearance, whereas low clearance (<20% hepatic blood flow) was observed in the rat, and high clearance (>70% hepatic blood flow) was seen in the mouse. The concentration-time profiles indicated the possibility of enterohepatic recirculation; subsequent studies in bile duct-cannulated rats demonstrated extensive biliary excretion of an acyl-glucuronide of SB-265123. In allometric scaling to predict the disposition of SB-265123 in humans, various standard correction factors were applied, including protein binding, maximum lifespan potential, and brain weight; each failed to produce adequate interspecies scaling of clearance (r(2) < 0.72). Consequently, a novel correction factor incorporating bile flow and microsomal UDP-glucuronosyltransferase activity in each species was applied, demonstrating substantial improvement in the correlation of the allometric plot (r(2) = 0.96). This study demonstrates a novel allometric correction that may be applicable to compounds that undergo conjugation and biliary excretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Lave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184 · cited 2×
“As a partial validation, this novel correction factor was applied to the data of Lave et al. (1996) for tolcapone.”
Scaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90
Mahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72
Cited by
Therapeutic antagonists and conformational regulation of integrin function
Shimaoka, M., & Springer, T. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1174 · Cited by 349
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.603 · Cited by 212
Self-citationMAHMOOD, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.015 · Cited by 170
Huang, Q., & Riviere, J. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.934671 · Cited by 149
“Other correction factors are also reported in the literature, including GFR for renally excreted drugs (CL/GFR = a w) [2] and bile flow rate and microsomal uridine diplosphate glucuronyltransferase (UDPGT) activity for biliary excreted drugs (CL BileFlow = a W and CL UDPGT = a W) [2,19,20].”
BackgroundNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Self-citation
Metadata
- Authors
- Ward, K. W., Azzarano, L. M., Bondinell, W. E., Cousins, R. D., Huffman, W. F., Jakas, D. R., Keenan, R. M., Ku, T. W., Lundberg, D., Miller, W. H., Mumaw, J. A., Newlander, K. A., Pirhalla, J. L., Roethke, T. J., Salyers, K. L., Souder, P. R., Stelman, G. J., & Smith, B. R.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 1999-11
- Volume
- 27
- Issue
- 11
- Pages
- 1232-1241
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2198743295
- Cited by
- 39
- References
- 5
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist. https://app.cochat.ai/papers/10.1016/s0090-9556(24)14923-9
- The paper
- Ward, K. W., Azzarano, L. M., Bondinell, W. E., Cousins, R. D., Huffman, W. F., Jakas, D. R., Keenan, R. M., Ku, T. W., Lundberg, D., Miller, W. H., Mumaw, J. A., Newlander, K. A., Pirhalla, J. L., Roethke, T. J., Salyers, K. L., Souder, P. R., Stelman, G. J., & Smith, B. R. (1999). Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist. Drug Metabolism and Disposition. https://doi.org/10.1016/s0090-9556(24)14923-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.